Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Pituitary Neoplasms 3Pituitary ACTH Hypersecretion 2Acromegaly 2Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Brain Neoplasms 1Adrenocortical Hyperfunction 1

Interventions

Prednisone 102enzalutamide 74Docetaxel 72Abiraterone Acetate 67Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 37apalutamide 28Prednisolone 27bicalutamide 26Zoledronic Acid 24pembrolizumab 22Goserelin 22radium Ra 223 dichloride 21darolutamide 21Triptorelin Pamoate 17cabazitaxel 15Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Cabergoline × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡